Predicting stable treatment response in patients with major depression treated with Hypericum extract WS 5570/5572

被引:10
作者
Kieser, M
Szegedi, A
机构
[1] Dr Willmar Schwabe Pharmaceut, D-76209 Karlsruhe, Germany
[2] Univ Med Berlin, Charite, Klin & Hochschulambulanz Psychiat & Psychotherapi, D-14050 Berlin, Germany
关键词
D O I
10.1055/s-2005-873153
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Recent research with several synthetic antidepressants indicates that early improvement during the initial weeks of treatment may be a highly sensitive predictor of therapeutic success in major depression. We investigated whether early improvement is sensitive and specific in predicting sustained response and non-response to antidepressant treatment with Hypericum extract WS (R) 5570/5572 and whether the results reported for synthetic antidepressants apply to these Hypericum extracts as well. Methods: We analyzed original data of 3 double-blind, randomized trials including a total of 594 adult outpatients suffering from major depression according to DSM-IV criteria, who received well-characterized Hypericum extract preparations WS (R) 5570, WS (R) 5572, WS (R) 5573 or placebo for 6 weeks. The main outcome measure was the prediction of a sustained >= 50% decrease of the Hamilton Depression Scale (HAM-D) total score versus baseline ('sustained response') by the presence of >= 20% HAM-D total score improvement after 1 and 2 weeks of treatment ('early improvement'). Results: For Hypericum extract, early improvement had a sensitivity of 87% (95 confidence interval [CI], 82-93%) and a specificity of 54% (95% Cl, 45-62%) at day 14, and a sensitivity of 43% (95% CI, 35-51%) and a specificity of 86% (95% Cl, 80-92%) at day 7 for predicting sustained response. After 2 weeks of treatment, 78% (95% Cl, 69-87%) of the patients who failed to improve did not show sustained response later during treatment. Conclusion: A substantial fraction of the patients treated with Hypericum extracts WS (R) 5570/5572 showed a meaningful reduction of depressive symptoms during the first two weeks of treatment (early improvement), which was found to be a sensitive predictor of sustained response. The results determined for the herbal extracts were comparable to those for effective synthetic antidepressants investigated previously.
引用
收藏
页码:194 / 200
页数:7
相关论文
共 41 条
[1]  
American Psychiatric Association, 2000, Text revision (DSM-IV-TR), V4th, DOI [10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr, DOI 10.1176/DSM10.1176/APPI.BOOKS.9780890420249.DSM-IV-TR]
[2]  
[Anonymous], J CLIN PSYCHIAT S4
[3]   St John's wort (Hypericum perforatum L.):: a review of its chemistry, pharmacology and clinical properties [J].
Barnes, J ;
Anderson, LA ;
Phillipson, JD .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (05) :583-600
[4]   Mirtazapine compared with paroxetine in major depression [J].
Benkert, O ;
Szegedi, A ;
Kohnen, R .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (09) :656-663
[5]  
CHARNEY DS, 1998, AM PSYCHIAT TXB PSYC
[6]  
Frank AJV, 2001, POE STUD-DARK ROMAN, V34, P1
[7]  
Franke L, 2003, PHARMACOPSYCHIATRY, V36, P134
[8]   Depression - A call for papers [J].
Glass, RM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (11) :1400-1401
[9]  
HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]
[10]  
Harrison P, 1998, CAN MED ASSOC J, V158, P637